Oncosimis Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -23.80%
- Profit Growth -77.04%
- Ebitda -97.65%
- Net Worth 28.06%
- Total Assets 7.16%
About Oncosimis Biotech
Oncosimis Biotech Private Limited (OBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 05 December 2016 (Eight years and one month 27 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Oncosimis Biotech Private Limited India is Sudarsanareddy Lokireddy as CEO.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24290TG2016PTC113241
-
Company No.
113241
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Dec 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Oncosimis Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudarsanareddy Lokireddy
|
Managing Director | 05-Dec-2016 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Lokireddy Reddy
|
Director | 05-Dec-2016 | Current |
Financial Performance of Oncosimis Biotech.
Oncosimis Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.8% decrease. The company also saw a substantial fall in profitability, with a 77.04% decrease in profit. The company's net worth Soared by an impressive increase of 28.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncosimis Biotech?
In 2023, Oncosimis Biotech had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Leafgen Biotech Private LimitedLokireddy Reddy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oncosimis Biotech?
Unlock and access historical data on people associated with Oncosimis Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncosimis Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncosimis Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
